Recurrent hemolytic uremic syndrome caused by DGKE gene mutation: a case report
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury without any association with preceding diarrhea. Dysregulation of the complement system is the most common cause of aHUS, and monoclonal humanized anti-C5 antibodies are now recommended as the first-line treatment for aHUS. However, if the complement pathway is not the cause of aHUS, C5 inhibitors are ineffective. In this study, we report the second reported case of aHUS caused by DGKE mutations in Republic of Korea. The patient was an 11-month-old infant who presented with prodromal diarrhea similar to typical HUS, self-remitted with conservative management unlike complement-mediated aHUS but recurred with fever. While infantile aHUS often implies genetic dysregulation of the complement system, other rare genetic causes, such as DGKE mutation, need to be considered before deciding long-term treatment with C5 inhibitors.
Abstract
Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury without any association with preceding diarrhea. Dysregulation of the complement system is the most common cause of aHUS, and monoclonal humanized anti-C5 antibodies are now recommended as the first-line treatment for aHUS. However, if the complement pathway is not the cause of aHUS, C5 inhibitors are ineffective. In this study, we report the second reported case of aHUS caused by DGKE mutations in Republic of Korea. The patient was an 11-month-old infant who presented with prodromal diarrhea similar to typical HUS, self-remitted with conservative management unlike complement-mediated aHUS but recurred with fever. While infantile aHUS often implies genetic dysregulation of the complement system, other rare genetic causes, such as DGKE mutation, need to be considered before deciding long-term treatment with C5 inhibitors.
참고문헌 (12)
- Loirat C, "Complement and the atypical hemolytic uremic syndrome in children", Pediatr Nephrol, 23, pp.1957~1972 (2008)
- Geerdink LM, "Atypical hemolytic uremic syndrome in children : complement mutations and clinical characteristics", Pediatr Nephrol, 27, pp.1283~1291 (2012)
- Loirat C, "An international consensus approach to the management of atypical hemolytic uremic syndrome in children", Pediatr Nephrol, 31, pp.15~39 (2016)
- McNamara LA, "High risk for invasive meningococcal disease among patients receiving eculizumab(Soliris)despite receipt of meningococcal vaccine", MMWR Morb Mortal Wkly Rep, 66, pp.734~737 (2017)
- Nester CM, "Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?", Hematology Am Soc Hematol Educ Program, 2012, pp.617~625 (2012)
- Lee JM, "Atypical hemolytic uremic syndrome : Korean pediatric series", Pediatr Int, 57, pp.431~438 (2015)
- Lemaire M, "Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome", Nat Genet, 45, pp.531~536 (2013)
- Bezdicka M, "Various phenotypes of disease associated with mutated DGKE gene", Eur J Med Genet, 63, pp.103953~ (2020)
- Azukaitis K, "The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol kinase ε", J Am Soc Nephrol, 28, pp.3066~3075 (2017)
- Mele C, "Characterization of a new DGKE intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome", Clin J Am Soc Nephrol, 10, pp.1011~1019 (2015)
- Noris M, "Atypical hemolytic-uremic syndrome", N Engl J Med, 361, pp.1676~1687 (2009)
- Husain D, "Atypical hemolytic uremic syndrome due to DGKE mutation and response to eculizumab : lessons for the clinical nephrologist", J Nephrol, 34, pp.1331~1335 (2021)